Bio-Techne Corp TECH
72.61
0.04
0.06%
as of 25 Sep
- Market cap
- $11.4B
- P/E
- 62.1×
Follow TECH
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Bio-Techne Corp (TECH) Debt to equity
Bio-Techne Corp's debt to equity at the end of the quarter to 30 June 2026 was 0.1×. Over the past ten years it has ranged from 0.1× (fiscal 2015) to 0.4× (fiscal 2019); the current reading is higher than 17% of that period. That is above the Biotechnology industry median of 0.0× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Annual
| Period | Debt to equity | Change |
|---|---|---|
| FY2026 | 0.1× | (47.37%) |
| FY2025 | 0.2× | 16.93% |
| FY2024 | 0.2× | (16.01%) |
| FY2023 | 0.2× | 22.07% |
| FY2022 | 0.2× | (30.76%) |
| FY2021 | 0.2× | (15.91%) |
| FY2020 | 0.3× | (40.40%) |
| FY2019 | 0.4× | 37.94% |
| FY2018 | 0.3× | (13.20%) |
| FY2017 | 0.4× | 233.33% |
Quarterly
| Period | Debt to equity | Change |
|---|---|---|
| Jun 2026 | 0.1× | (1.04%) |
| Mar 2026 | 0.1× | (25.83%) |
| Dec 2025 | 0.1× | (15.27%) |
| Sep 2025 | 0.2× | (15.36%) |
| 42 more quarters | Free account |
Against its own ten years
Low 0.1×
High 0.4×
Ten-year median
0.2×
Current reading's percentile
17
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| BBIO BridgeBio Pharma, Inc. compare | −0.8× |
| CORT Corcept Therapeutics Incorporated compare | 0.0× |
| KRYS Krystal Biotech, Inc. compare | 0.0× |
| SMMT Summit Therapeutics PLC compare | 0.0× |
| TECH Bio-Techne Corp | 0.1× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 0.7× |
| BMRN BioMarin Pharmaceutical Inc. compare | 0.7× |
| AXSM Axsome Therapeutics, Inc. compare | 1.5× |
| HALO Halozyme Therapeutics, Inc. compare | 15.0× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.2× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on TECH
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement